EMA Authorised: Rixathon (rituximab) — Sandoz GmbH

View source ↗

Summary

EMA authorised Rixathon (rituximab) by Sandoz as a biosimilar to Rituxan for several autoimmune and hematologic diseases, expanding access to rituximab therapy.…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Granulomatosis with Polyangiitis
• Microscopic Polyangiitis
• Non-hodgkin Lymphoma
• Pemphigus
• Rheumatoid Arthritis

Drugs mentioned

• Rixathon (rituximab)

Snippet

Status: Authorised. Therapeutic area: Lymphoma, Non-Hodgkin;Arthritis, Rheumatoid;Leukemia, Lymphocytic, Chronic, B-Cell;Wegener Granulomatosis;Microscopic Polyangiitis;Pemphigus. MAH: Sandoz GmbH. Decision date: 10/07/2025